전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-3 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
AntibodyLimited DatastaleOslo University HospitalPhase 2

pembrolizumab (Keytruda, LTX-315 + pembrolizumab)

Melanoma Stage IIIB-IV · Melanoma Stage IIIB-IV

#MelanomaStageIIIB-IV#Antibody#Phase2#monoclonal-antibody#Oslo
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-20SP cells (LUCAR-20SP cells)

Relapsed B-cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-G79 T cells (LUCAR-G79 T cells)

Relapsed/Refractory Autoimmune Diseases · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

LV20.19 CAR T cells (LV20.19 CAR T cells)

Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
ADCLimited DatastaleGilead SciencesPhase 2

LG (Labetuzumab Govitecan, Labetuzumab Govitecan (LG))

Metastatic Colorectal Cancer; Colon Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#ADC#Phase2#antibody-drug-conjugate#ColonCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 3

Lenalidomide and rituximab (R2, Lenalidomide and rituximab, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.)

Follicular Lymphoma (FL) · Follicular Lymphoma (FL)

#FollicularLymphomaFL#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Recruiting
CGTLimited DatastaleIovance Biotherapeutics, Inc.Phase 3

pembrolizumab (Keytruda, Lifileucel plus Pembrolizumab)

Metastatic Melanoma; Unresectable Melanoma · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase3#monoclonal-antibody#UnresectableMelanoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAbbViePhase 3

Livmoniplimab (Livmoniplimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Recruiting
AntibodyLimited DatastaleADC TherapeuticsPhase 1

durvalumab (Imfinzi, Loncastuximab Tesirine and Durvalumab)

Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase1#monoclonal-antibody#MantleCellLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastaleBayerPhase 1

BAY1129980 (Lupartumab Amadotin, Lupartumab Amadotin (BAY1129980))

Neoplasms · Neoplasms

#Neoplasms#Antibody#Phase1#monoclonal-antibody#Bayer
Trials 1Status Discontinued
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 2

MB-CART20.1 (MB-CART20.1)

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastalemAbxience Research S.L.Phase 1

Bevacizumab Biosimilar (MB02, MB02 (Bevacizumab Biosimilar))

Healthy Volunteers · Healthy Volunteers

#HealthyVolunteers#Antibody#Phase1#monoclonal-antibody#mAbxience
Trials 1Status Active
AntibodyLimited DatastaleMerus B.V.Phase 2

pembrolizumab (Keytruda, MCLA-158 + Pembrolizumab)

Advanced/Metastatic Solid Tumors; Colorectal Cancer · Advanced/Metastatic Solid Tumors

#AdvancedMetastaticSolidTumors#Antibody#Phase2#monoclonal-antibody#Advanced+3
Trials 1Status Recruiting
CGTLimited DatastaleTechnische Universität DresdenPhase 1

BCMA directed CAR T-cells (MDC-CAR-BCMA001, MDC-CAR-BCMA001 (BCMA directed CAR T-cells))

Neoplasms; Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleMedivirPhase 2

pembrolizumab (Keytruda, MIV-818, MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, fostroxacitabine bralpamide)

Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#IntrahepaticCholangiocarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleCentre Hospitalier Universitair…Phase 2

durvalumab (Imfinzi, MP0317 + Gemcitabine + Cisplatine + Durvalumab)

Advanced Biliary Tract Carcinoma · Advanced Biliary Tract Carcinoma

#AdvancedBiliaryTractCarcinoma#Antibody#Phase2#monoclonal-antibody#Centre
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab+Cisplatin (MRG003 combined with Pucotenlimab+Cisplatin)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleMyeloid TherapeuticsPhase 1

atezolizumab (Tecentriq, MT-303 +Atezolizumab + Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase1#monoclonal-antibody#Myeloid
Trials 1Status Recruiting
CGTLimited DatastaleCelladon CorporationPhase 2

MYDICAR Phase 1 (MYDICAR Phase 1)

Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy · Ischemic Cardiomyopathy

#IschemicCardiomyopathy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued

37 / 51 pages

← PreviousNext →